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We recently proposed that competitive endogenous
RNAs (ceRNAs) sequester microRNAs to regulate
mRNA transcripts containing common microRNA
recognitionelements (MREs).However, the functional
role of ceRNAs in cancer remains unknown. Loss of
PTEN, a tumor suppressor regulated by ceRNA
activity, frequently occurs in melanoma. Here, we
report thediscovery of significant enrichment of puta-
tive PTEN ceRNAs among genes whose loss acceler-
ates tumorigenesis following Sleeping Beauty inser-
tional mutagenesis in a mouse model of melanoma.
We validated several putative PTEN ceRNAs and
further characterized one, the ZEB2 transcript. We
show that ZEB2 modulates PTEN protein levels in
amicroRNA-dependent, protein coding-independent
manner.AttenuationofZEB2expressionactivates the
PI3K/AKT pathway, enhances cell transformation,
and commonly occurs in human melanomas and
other cancers expressing low PTEN levels. Our study
genetically identifies multiple putative microRNA
decoys for PTEN, validates ZEB2 mRNA as a bona
fide PTEN ceRNA, and demonstrates that abrogated
ZEB2 expression cooperates with BRAFV600E to
promote melanomagenesis.
INTRODUCTION
Melanoma is estimated to affect more than 70,000 people in the
US in the year 2011 and, despite extensive research and clinical382 Cell 147, 382–395, October 14, 2011 ª2011 Elsevier Inc.efforts, remains fatal in the majority of patients with metastatic
disease (http://www.cancer.gov/). Aberrant activation of the
MAPK-signaling pathway plays a central role in melanoma
development, as exemplified by the frequent occurrence of acti-
vating mutations in BRAF (Brose et al., 2002; Davies et al., 2002).
Genetic and molecular analyses have demonstrated that onco-
genic BRAFV600E represents an initiating event in the evolution
of melanoma (Davies et al., 2002). Indeed, 80% of human nevi
harbor a BRAFV600E mutation (Pollock et al., 2003). Moreover,
mouse models of BRAFV600E develop melanoma only after a
long latency and with incomplete penetrance (Dankort et al.,
2009; Dhomen et al., 2009; F.A.K., D.P., and D.A.T., unpublished
data), suggesting that additional mutations are required for the
formation of frankmalignancy. Silencing of the tumor suppressor
PTEN represents one such mutation and is observed in30% of
human melanoma cases (Tsao et al., 2004). In mice, complete or
partial PTEN loss dramatically accelerates BRAFV600E-induced
melanoma (Dankort et al., 2009), thus highlighting the oncogenic
potential of combined hyperactivation of PI3K/AKT and MAPK
signaling.
MicroRNAs (miRNAs) have been shown to regulate PTEN
and thus contribute to cell transformation mediated by aberrant
activation of the PI3K/AKT pathway (Poliseno et al., 2010a).
miRNAs are endogenous, noncoding22 nucleotide RNAmole-
cules that bind to microRNA response elements (MREs) con-
tained in their target mRNAs (Bartel, 2009; Thomas et al.,
2010). This association recruits the RNA-induced silencing
complex (RISC) to target mRNA transcripts, thereby antago-
nizing their stability and/or translation (Bartel, 2009; Thomas
et al., 2010). miRNA-mediated modulation of mRNA levels is
conserved in most eukaryotic organisms and is considered
a mechanism to fine-tune gene expression. In recent years,
numerous examples of abnormal gene regulation by miRNA
misexpression have been demonstrated to contribute to patho-
logical conditions (http://202.38.126.151/hmdd/mirna/md/).
mRNAs harbor multiple MREs and thus can be regulated by
several miRNAs, and miRNAs are known to target dozens of
mRNA transcripts. The fact that distinct RNA molecules can be
targeted by common miRNAs led us to propose that related
highly homologous mRNAs, such as gene-pseudogene pairs,
may act as miRNA decoys for each other. Pseudogenes are
considered ‘‘junk DNA,’’ as they lack a protein coding function
(D’Errico et al., 2004). However, by binding to common miRNAs,
pseudogene mRNAs may maintain the balance between their
ancestral genes and such miRNAs. Indeed, we have recently
demonstrated that the PTEN pseudogene transcript PTENP1
regulates the levels of PTEN through sequestration of shared
miRNAs (Poliseno et al., 2010b).
On this basis, we further hypothesized that the concept of gene
regulation by competition for common miRNAs is not limited to
pseudogenes and can be extended to mRNAs and long noncod-
ing RNAs and have termed RNA molecules that act as miRNA
decoys as ‘‘competitive endogenous RNAs’’ (ceRNAs) (Salmena
et al., 2011). Importantly, we proposed that the mRNA and the
protein encoded by ceRNAgenesmay be involved in distinct bio-
logical processes (Salmena et al., 2011). Employing bio-
informatics-guided prediction methods of MRE overlap, we
have discovered that multiple mRNAs serve as ceRNAs for
PTEN (Tay et al., 2011 [this issue of Cell]). Importantly, the
proteins encoded by PTEN ceRNAs have thus far not been asso-
ciated with the regulation of PTEN, supporting the notion that, in
some instances, mRNAs and the proteins that they encode may
be involved in distinct biological processes.
Our recent work suggests that mRNAs may act as tumor
suppressors or oncogenes through their ceRNA activity.
However, whether aberrant ceRNA expression is associated
with cancer development in general and whether loss of PTEN
ceRNAs promotes BRAFV600E-induced melanoma in vivo in
particular are unknown. Here, we report a striking enrichment
for PTEN ceRNAs among genes that were identified in a trans-
posonmutagenesis screen in an oncogenic BRAF-driven mouse
model of melanoma. Detailed functional analysis of one such
putative PTEN ceRNA, ZEB2, validated its protein-independent
and miRNA-dependent ability to regulate PTEN expression.
Moreover, we show that ZEB2 and PTEN are coregulated and
that ZEB2 levels are commonly attenuated in human cancers.
RESULTS
Identification of Putative PTEN ceRNAs Using In Vivo
Sleeping Beauty Insertional Mutagenesis
Oncogenic BRAFV600E is an initiating mutation in melanoma, and
whereas some other mutations such as loss of PTEN commonly
occur in melanoma, the full spectrum of tumor-promoting
genetic events remains to be determined. To this end, we per-
formed a forward genetic screen utilizing the Sleeping Beauty
transposon system in a B-RafV619E-driven mouse model of
melanoma (Figure S1 and Extended Experimental Procedures
available online), in which B-RafV619E corresponds to human
BRAFV600E. A detailed description and in-depth analysis of this
screen will be reported elsewhere (F.A.K., D.P., and D.A.T.,unpublished data). In brief, we created mutant mice that carried
the following alleles: LoxP-STOP-LoxP-B-RafV619E (LSL-B-
RafV619E; F.A.K., D.P., and D.A.T., unpublished data), Tyrosi-
nase-CreERt2 (TyrCreERt2 [Bosenberg et al., 2006]), rosa26-
LoxP-STOP-LoxP-SleepingBeauty13 (LSL-SB; P.A.P.-M. and
D.A.T., unpublished data), and T2Onc (Collier et al., 2005). Treat-
ment of compound mutant LSL-B-RafV619E; TyrCreERt2; LSL-
SB; T2Onc mice with 4-OH Tamoxifen activated the melano-
cyte-specific Cre, leading to excision of the STOP cassettes
and expression of endogenous oncogenic B-Raf and SB13.
Sleeping Beauty transposase-mediated ‘‘hopping’’ of the
T2Onc transposon resulted in insertional mutagenesis, thereby
accelerating melanoma development (Figures 1A and S1 and
data not shown). 454 sequencing of genomic melanoma DNA
identified 320 genes with a significant enrichment of transposon
insertions, termed ‘‘common insertion sites’’ (CIS). Importantly,
PTEN was among the most significant CIS (data not shown),
thus demonstrating the ability of our Sleeping Beauty mutagen-
esis approach to identify key genes altered in melanoma.
As loss of PTEN expression cooperates with BRAFV600E (Dan-
kort et al., 2009; Tsao et al., 2004) and PTEN expression is regu-
lated by ceRNAs (Poliseno et al., 2010b; Tay et al., 2011), we
sought to determine whether Sleeping Beauty identified putative
PTEN ceRNAs that cooperate with B-RafV619E to accelerate
melanoma development (Figure 1A). We performed a mutually
targeted MRE enrichment (MuTaME) analysis (Figure 1B; Tay
et al., 2011) using the TargetScan prediction algorithm (Friedman
et al., 2009; Grimson et al., 2007; Lewis et al., 2005; http://www.
targetscan.org) for MREs located in 30UTRs. We postulated that
the ability of any given mRNA to act as a miRNA decoy for PTEN
increases with the number ofMREs that they share. The 30UTRof
murine PTEN was predicted to contain MREs for 39 different
miRNAs (Table S1). We set a stringent cutoff of at least seven
shared MREs between PTEN and putative PTEN ceRNAs for
the MuTaME analysis (Figure 1B). Using these conditions, we
identified 33 candidate PTEN ceRNAs among the 320 CIS
discovered in the Sleeping Beauty screen (Figure 1C). Notably,
this represented a significant enrichment of putative PTEN
ceRNAs (p = 7.76 3 1011), as the MRE-based overlap with
PTEN expected by chance was only approximately nine genes.
Thus, our Sleeping Beauty approach uncovered putative PTEN
ceRNAs that promote cancer in an in vivo model of melanoma.
We ranked the 33 putative PTEN ceRNAs according to their
similarity with PTEN (Figure 2A). The similarity score is based
on a Poisson distribution: we used a linear combination, with
equal and opposite weights, of the dissimilarity based on distinct
occurrences and the additive similarity as defined previously
(van Helden, 2004). This approach utilized all miRNAs predicted
by TargetScan and the total number of their MREs located in the
30UTRs to obtain the similarity score for each CIS. Furthermore,
most candidate PTEN ceRNAs contain several MREs for the
same miRNAs, and thus the total numbers of MREs shared
with PTEN are even greater (Table S1).
PTEN ceRNAs Modulate Expression of PTEN
To examine whether the identified putative PTEN ceRNAs regu-
late expression of PTEN, we performed RNAi-mediated gene
silencing in human melanoma cells using pools of four siRNAsCell 147, 382–395, October 14, 2011 ª2011 Elsevier Inc. 383
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Figure 1. Identification of Putative PTEN
ceRNAs
(A) Schematic outline of our hypothesis: onco-
genic BRAF mediates the transformation from
melanocytes to nevi, and additional loss of PTEN
promotes progression to melanoma. PTEN
expression is regulated by PTEN ceRNAs, which
sequester PTEN-targeting miRNAs. Transposon
insertion into ceRNA gene loci suppresses their
expression, which results in increased availability
of PTEN-targeting miRNAs and a reduction of
PTEN expression.
(B) Bioinformatics approach to identify putative
PTEN ceRNAs among Sleeping Beauty CIS. MREs
predicted by TargetScan in the murine PTEN
30UTR were utilized for a mutually targeted MRE
enrichment (MuTaME) analysis to determine MRE
overlap between PTEN and Sleeping Beauty CIS.
CIS that share seven or more MREs with PTEN
were considered putative PTEN ceRNAs.
(C) Enrichment of putative PTEN ceRNAs among
Sleeping Beauty CIS. The Sleeping Beauty screen
identified 320 CIS, 33 of which are putative PTEN
ceRNAs. This enrichment is highly significant (p =
7.76 3 1011).
See also Table S1 and Figure S1.to reduce off-target effects. We selected eight putative PTEN
ceRNAs (AFF1, DCBLD2, JARID2, MBNL1, RBM9, TNRC6a,
TNRC6b, and ZEB2) and depleted them in WM35 cells (Fig-
ure 2B). Knockdown of seven genes led to reduction of PTEN,
six of which significantly attenuated PTEN expression (AFF1,
JARID2, MBNL1, RBM9, TNRC6a, TNRC6b, and ZEB2). A
reduction of PTENmRNA levels following PTEN ceRNA silencing
was also evident in WM35 cells (Figure S2A). In a second human
melanoma cell line, A375, decreased PTEN expression was also
observed following PTEN ceRNA knockdown, albeit at lower
levels (Figures S2C and S2D). The knockdown efficiencies are
shown in Figures S2B and S2E. Interestingly, in some instances,384 Cell 147, 382–395, October 14, 2011 ª2011 Elsevier Inc.depletion of PTEN resulted in downregu-
lation of the putative PTEN ceRNA
(Figures S2B and S2E), indicating that
the regulatory relationship between
PTEN and PTEN ceRNAs might be
reciprocal. Importantly, we found that
CNOT6L, a PTEN ceRNA that we pre-
dicted using the rna22 algorithm and vali-
dated in prostate cancer (Tay et al., 2011),
was a CIS identified by Sleeping Beauty.
Similar to its ceRNA function in prostate
cancer cells (Tay et al., 2011), siRNA-
mediated knockdown of CNOT6L signifi-
cantly reduced PTEN expression in both
human melanoma cell lines (Figures 2B
and S2C).
Critically, the T2Onc transposons in-
serted in PTEN and the putative PTEN
ceRNAs in both orientations throughout
the genes (Figure S2F). This insertionpattern is indicative of gene repression via the polyadenylation
signals rather than gene activation by the MSCV promoter
(Collier et al., 2005). Thus, these CIS are likely tumor suppres-
sors. Taken together, these results indicate that the candidate
ceRNAs identified by Sleeping Beauty may indeed act as
tumor-suppressive ceRNAs for PTEN.
ZEB2 Silencing Results in Attenuated PTEN Expression
As silencing of several of the putative PTEN ceRNAs led to
reduced PTEN protein levels, we sought to further validate
and characterize the ability of a CIS mRNA to function as
a PTEN ceRNA. None of the seven CIS that reduced PTEN
Gene 
symbol
Similarity 
score
Common 
MREs
Pten 1.000 39
Tnrc6b 0.625 27
Zfp148 0.336 16
Taok1 0.287 14
Ubn2 0.280 14
Lrch1 0.253 12
Dcbld2 0.245 12
Cask 0.244 12
Epc2 0.210 10
Bach2 0.209 11
Mll1 0.207 11
0.206 11
Tnrc6a 0.197 10
Mbnl1 0.194 10
Epc1 0.192 10
Chd9 0.177 9
Jarid2 0.176 9
Dtna 0.168 9
Zeb2 0.166 9
Aff1 0.158 8
Etv6 0.154 8
Prickle2 0.153 8
Ank3 0.151 8
Rbm9 0.143 8
Rapgef2 0.137 8
Kcna1 0.131 8
Zeb1 0.127 7
Csmd1 0.126 7
Cdk13 0.125 7
Asxl2 0.124 7
Dip2c 0.123 7
Rock2 0.119 7
Slc6a6 0.117 7
Fndc3b 0.111 7
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Figure 2. Putative PTEN ceRNAs Modulate
PTEN Expression Levels
(A) List of candidate PTEN ceRNAs identified by
Sleeping Beauty. The 33 putative PTEN ceRNAs
are ranked by their similarity score, which is based
on the identity and number of MREs, as well as the
length of the CIS 30UTRs. The number of MREs
shared between PTEN and the individual CIS is
also shown.
(B) Western blot (top) and quantification (bottom)
of siRNA-mediated knockdowns of putative
PTEN ceRNAs in WM35 human melanoma cells.
HSP90 expression is shown as a loading control,
and PTEN expression levels were normalized to
HSP90.
(C) Transposon insertion does not increase
expression of the ZEB2 30UTR (left) or PTEN 30UTR
(right). qRT-PCR depicting the ratio between ZEB2
50UTR and 30UTR expression levels in melanomas
with transposon insertions in CDKN2A, PTEN, or
ZEB2 is shown.
(D) Melanomas with ZEB2 transposon insertions
express less PTEN. Western blot showing
expression of PTEN and ZEB2 in melanomas iso-
lated from LSL-B-RafV619E; TyrCreERt2 mice
(control) or LSL-B-RafV619E; TyrCreERt2; LSL-SB;
T2Onc mice with a transposon insertion in either
PTEN (CIS: PTEN) or ZEB2 (CIS: ZEB2). Quantifi-
cation of the western analysis is shown in the
bottom panel. Note that PTEN and ZEB2 expres-
sion is diminished in tumors with either PTEN or
ZEB2 insertions.
NC, negative control (nontargeting siRNA pool).
Data are represented as mean ± SEM. See also
Figure S2.levels in WM35 melanoma cells code for a known tumor
suppressor protein. The ZEB2 protein, however, has been well
established as an activator of the epithelial-to-mesenchymal
transition (EMT) (Gregory et al., 2008; Vandewalle et al., 2005)
and therefore plays a critical role in the progression of epithelial
cancers. Whether the ZEB2 protein is protumorigenic in mela-
noma is unknown; however, as a PTEN ceRNA, the ZEB2
mRNA may be tumor suppressive. Given the potentially distinct
function of the ZEB2 protein and transcript, we decided to
examine whether ZEB2 mRNA exerts a tumor-suppressive
function in melanoma through its competition for PTEN-target-
ing miRNAs.
Transposon insertions in the 50-30 orientation in the ZEB2 locus
could theoretically allow for overexpression of the ZEB2 30UTR,
whichwould potentially sequester miRNAs from PTEN and result
in elevated PTEN levels. To ascertain that the ZEB2 30UTR is not
overexpressed in melanomas with such insertions, we analyzed
the expression ratio of the ZEB2 50UTR and 30UTR. Importantly,
we observed a 1:1 ratio of expression in all cases, thus excludingCell 147, 382–395,overexpression of the 30UTR (Figure 2C).
As an additional control, we tested the
effects of transposon insertion in the
PTEN locus. Similarly, tumors with trans-
poson insertions in the 50-30 orientation
did not display an increase in the PTEN30UTR:50UTR ratio (Figure 2C), indicating that the transposon
acts as a gene trap in these cases. We further tested whether
ZEB2 protein levels are affected by transposon insertions.
PTEN and ZEB2 are readily detectable by immunoblotting in
melanomas without transposon insertions (Figure 2D, lanes
1–4). In contrast, transposon insertion in either PTEN (Figure 2D,
lanes 5–7) or ZEB2 (Figure 2D, lanes 8–10) reduced expression of
both proteins (Figure 2D). These data confirm that transposon
insertion in PTEN and ZEB2 represses gene expression and indi-
cate that ZEB2 reduction modulates protein levels of PTEN.
Moreover, the decrease in ZEB2 expression in tumors with
a PTEN transposon insertion suggests that the PTEN-ZEB2
miRNA decoy mechanism may be reciprocal.
To further examine the regulation of PTEN by ZEB2 via miRNA
sequestration, we used pools of four siRNAs to deplete PTEN or
ZEB2 in a primary murine melanoma cell line, TB13602, isolated
from a LSL-B-RafV619E; TyrCreERt2 mouse. Knockdown of
ZEB2 in TB13602 cells reduced PTEN protein levels by 60%
(Figure 3A). RNAi-mediated silencing of PTEN led to a slightOctober 14, 2011 ª2011 Elsevier Inc. 385
PTEN
ZEB2
HSP90
siRNA: PTEN ZEB2 NC
0.0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
Pten Zeb2
re
la
tiv
e 
pr
ot
ei
n 
e
xp
re
ss
io
n
siPten
siZeb2
NC**
A
***
B
0.0
0.2
0.4
0.6
0.8
1.0
1.2
PTEN ZEB2
re
la
tiv
e 
 m
R
N
A 
e
xp
re
ss
io
n
***
**
TB13602
0.0
0.2
0.4
0.6
0.8
1.0
1.2
PTEN ZEB2
siPTEN
siZEB2
NC
WM35
***
***
***
***
0.0
0.2
0.4
0.6
0.8
1.0
1.2
PTEN ZEB2
A375
***
***
0.0
0.2
0.4
0.6
0.8
1.0
1.2
re
la
tiv
e 
 P
TE
N
 e
xp
re
ss
io
n
******
***
*
A375 WM35
PTEN ZEB2 NC
A375
PTEN ZEB2 NC
WM35
AKT
ZEB2
siRNA:
PTEN
pAKT
0
2
4
6
8
10
12
re
la
tiv
e 
 p
AK
T 
e
xp
re
ss
io
n
A375 WM35
***
**
*
*
0
1
2
3
4
5
siZEB2 NC
pA
KT
 
 
/ t
ot
al
 A
KT
0 min
5 min
10 min
30 min
90 min
ZEB2
PTEN
AKT
pAKT
min FCS: 0 5 10 30 90 0 5 10 30 90 0 5 10 30 90
siPTEN siZEB2 NC
C D E
F G H
Figure 3. ZEB2 Depletion Downregulates PTEN
(A) ZEB2 silencing lowers PTEN protein levels in murinemelanoma cells TB13602.Western analysis for PTEN and ZEB2 expression andHSP90 as loading control
is shown in the left panel. Quantification of three independent western analyses is shown in the right panel.
(B) AKT activation kinetics in TB13602 cells following ZEB2 depletion. Cells were starved overnight and stimulated with 10% FCS-containing media for the
indicated time points. Western blots for phosphorylated AKT (pAKT), total AKT, ZEB2, and PTEN are shown in the left panel; quantification of pAKT is shown in the
right panel.
(C) ZEB2 silencing in humanmelanoma cell lines lowers PTEN expression and activates AKT. A375 andWM35melanoma cells lines were transfected with siRNA
pools against PTEN or ZEB2. Western analysis for PTEN, ZEB2, and phospho-AKT is shown. HSP90 and total AKT were used as loading controls.
(D) Quantification of PTEN expression in A375 and WM35 cells in three independent western analyses. PTEN expression was normalized to HSP90 levels.
(E) Quantification of AKT activation in A375 andWM35 cells in three independent western analyses. Phospho-AKT expression was normalized to total AKT levels.
(F) qRT-PCR analysis of PTEN and ZEB2 expression in TB13602 cells.
(G and H) qRT-PCR analyses of PTEN and ZEB2 expression in A375 (G) and WM35 (H) cells. Mouse and human siRNA pools against PTEN and ZEB2 efficiently
reduce PTEN and ZEB2 mRNA, respectively. Note the reciprocal effect of ZEB2 knockdown on PTEN expression levels and vice versa in WM35 cells.
NC, negative control (nontargeting siRNA pool). Data are represented as mean ± SEM. See also Figure S3.attenuation of ZEB2 expression (Figure 3A), similar to the results
obtained in melanomas with PTEN or ZEB2 CIS (Figure 2D).
As PTEN is a major antagonist of PI3K/AKT signaling, we
examined whether ZEB2-mediated reduction of PTEN activates386 Cell 147, 382–395, October 14, 2011 ª2011 Elsevier Inc.this pathway. ZEB2 depletion had no effect on AKT phosphory-
lation at steady-state levels (data not shown); however, upon
starvation and restimulation, ZEB2-depleted cells displayed
elevated AKT activation compared to control cells (Figure 3B).
We next analyzed whether ZEB2 acts as a PTEN ceRNA in
human melanoma cells. In four human melanoma cell lines,
PTEN protein levels were reduced following knockdown of
ZEB2 (Figures 3C, 3D, and S3A). Moreover, depletion of ZEB2
led to AKT activation in these cell lines (Figures 3C, 3E, and
S3A). Importantly, ZEB2 siRNAs without potential seed matches
to PTEN efficiently lowered PTEN levels in mouse and human
melanoma cells (Figure S3B), indicating that PTEN downregula-
tion is not due to off-target effects of the ZEB2 siRNA pools.
Interestingly, ZEB2 depletion had only minor and statistically
insignificant effects on PTEN mRNA levels in TB13602 and
A375 cells (Figures 3F and 3G), whereas it significantly reduced
PTEN transcript in WM35 cells (Figure 3H). These data suggest
that the miRNAs mediating the functional interaction of PTEN
and ZEB2 regulate mRNA stability in a cell line-dependent
fashion, whereas their control of translation is a more universal
phenomenon.
Repression of PTEN by ZEB2 Loss Is 30UTR and miRNA
Dependent
These in vitro and in vivo data support the notion that ZEB2 acts
as a PTEN ceRNA. They do not exclude, however, the transcrip-
tional regulation or protein stability as potential mechanisms of
ZEB2 loss-mediated PTEN reduction. We addressed these
possibilities by ectopic expression of a luciferase-PTEN30UTR
reporter construct in TB13602 cells, followed by knockdown of
PTEN or ZEB2. Silencing of either PTEN or ZEB2 increased
the availability of shared miRNAs, thereby suppressing the
luciferase-PTEN30UTR reporter as measured by diminished
luciferase activity (Figure 4A). Importantly, as the luciferase-
PTEN30UTR reporter construct is expressed from a CMV
promoter and does not code for a PTEN peptide, reduced lucif-
erase activity was dependent on the PTEN 30UTR, thus elimi-
nating transcriptional regulation and protein stability as explana-
tions for the ZEB2-PTEN functional interaction.
To exclude the involvement of RNA-binding proteins that
could regulate PTEN mRNA translation through its 30UTR, we
used cells deficient for the miRNA biogenesis protein Dicer to
examine whether ZEB2 controls PTEN levels in a miRNA-depen-
dent manner. In Dicer wild-type HCT116 colon carcinoma cells,
siRNA against ZEB2 lowered PTEN levels, similar to our observa-
tion in melanoma cells (Figure 4B). In contrast, ZEB2 depletion
failed to reduce PTEN expression in Dicer null HCT116 cells (Fig-
ure 4B). Moreover, ZEB2 knockdown decreased PTEN mRNA
only in Dicer wild-type cells, but not in Dicer-deficient cells (Fig-
ure 4C). Conversely, PTEN silencing resulted in diminished ZEB2
mRNA levels in Dicer wild-type HCT116 cells, which was
rescued in Dicer-deficient HCT116 cells (Figure 4C). Similar to
PTEN attenuation, AKT activation by ZEB2 silencing is only
evident in Dicer wild-type HCT116 cells (Figure 4D). These
data indicate that regulation of PTEN expression by ZEB2 is
indeed miRNA dependent.
As ablation of ZEB2 mRNA reduces PTEN expression due to
increased availability of common miRNAs, overexpression of
ZEB2 mRNA should have the opposite effect. However, ectopic
expression of full-length ZEB2mRNA would also increase ZEB2
protein. We therefore overexpressed only the ZEB2 30UTR to
uncouple potential effects of elevated ZEB2 protein on PTENexpression, such as transcriptional regulation, from the
miRNA-based regulation via MREs. This approach was also
used to show that the 30UTRs of other putative PTEN ceRNAs
increase PTEN levels in prostate cancer (Poliseno et al.,
2010b; Tay et al., 2011). We expressed the 30UTRs of ZEB2 or
PTEN in A375 and TB13602melanoma cells. Cells were cotrans-
fected with the luciferase-PTEN30UTR reporter construct to
measure the ceRNA activity of ectopically expressed 30UTRs
on transcripts containing the PTEN 30UTR. Critically, the ZEB2
30UTR significantly increased the activity of the luciferase-
PTEN30UTR reporter (Figures 4E and 4F). Moreover, PTEN
protein levels were increased when the PTEN and ZEB2 30UTRs
were overexpressed in A375 cells (Figure 4G) and Dicer wild-
type HCT116 cells (Figure 4H). Elevated expression of PTEN
was rescued by Dicer deficiency in HCT116 cells (Figure 4H).
Similarly, overexpression of the ZEB2 30UTR significantly
increased the activity of the luciferase-PTEN 30UTR reporter in
HCT116 cells, and Dicer deficiency partially negated this effect.
Critically, overexpression of the ZEB2 coding sequence had no
effect on PTEN protein levels in HCT116 cells (Figure S4).
Thus, depletion as well as overexpression of ZEB2 mRNA alters
the balance between PTEN mRNA and common miRNAs,
thereby impacting PTEN expression.
Analysis of miRNAs Common to PTEN and ZEB2
To elucidate which of the miRNAs predicted to target PTEN and
ZEB2 mediate the observed crosstalk, we further characterized
the effect of these miRNAs on PTEN and ZEB2 expression. First,
we interrogated which MREs were predicted to be common
between the 30UTRs of PTEN and ZEB2. TargetScan predicted
that PTEN and ZEB2 are targets for nine shared miRNA fami-
lies and that they contain a total of 14 and 16 MREs for these
miRNAs, respectively (Figure 5A). Of these miRNAs, several
have been validated as PTEN-targeting miRNAs (miR-25, miR-
32, miR-92ab, miR-141, miR-144, miR-363, and miR-367) (Lee
et al., 2010; Poliseno et al., 2010a; Zhang et al., 2010), whereas
only the miR-200 family has been validated as repressors of
ZEB2 (Gregory et al., 2008; Korpal et al., 2008; Park et al.,
2008). We next delivered miRNA mimics for one member of
each miRNA family predicted to target PTEN and ZEB2 to
TB13602 cells and analyzed PTEN and ZEB2 protein levels. Of
the ten miRNAs tested, four targeted PTEN and ZEB2 to some
extent (miR-181, miR-200b, miR-25, and miR-92a) (Figure 5B).
We next determined the expression levels of these ten miRNAs
in melanoma cells. Interestingly, miRNA expression levels were
similar between the three different melanoma cell lines analyzed
(Figure 5C), and all four miRNAs that target PTEN and ZEB2were
expressed in the melanoma cell lines (Figure 5C).
Next, we examined whether the four suppressive miRNAs
(miR-181, miR-200b, miR-25, and miR-92a) that are expressed
in melanoma associate with the 30UTRs of PTEN and ZEB2. To
this end, we performed RNA immunoprecipitations (RIPs) in
melanoma cells using the PTEN and ZEB2 30UTRs as baits.
Notably, all four miRNAs associated with the 30UTRs of PTEN
and ZEB2, and a control miRNA with no predicted MRE in
PTEN and ZEB2 bound neither 30UTR (Figure 5D). Furthermore,
knockdown of either PTEN or ZEB2 increased miRNA avail-
ability, as determined by increased association of miR-92aCell 147, 382–395, October 14, 2011 ª2011 Elsevier Inc. 387
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Figure 4. Regulation of PTEN by ZEB2 Is 30UTR and miRNA Dependent
(A) Effect of ZEB2 depletion on luciferase activity of a luciferase-PTEN30UTR reporter. Knockdown of PTEN (positive control) and ZEB2 reduces luciferase activity
measured in relative light units (RLU).
(B) ZEB2 depletion lowers PTEN expression in wild-type HCT116 colon cancer cells, but not in Dicer-deficient HCT116 cells. Western blot showing expression
of PTEN and HSP90 as loading control in wild-type and Dicer null HCT116 cells (top). (Bottom) Quantification of three independent western blot analyses.
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with the MS2-PTEN 30UTR bait mRNA (Figure 5E). Taken
together, ZEB2 sequesters at least four miRNAs (miR-181,
miR-200b, miR-25, and miR-92a) to regulate PTEN levels, and
ZEB2 downregulation increases the availability of at least one
of these miRNAs.
ZEB2 Displays Tumor-Suppressive Properties
in Melanoma Cells
As decreased PTEN expression drives the formation of
numerous types of cancer, we determined whether aberrant
control of PTEN by loss of ZEB2 enhanced oncogenic transfor-
mation of melanoma cells. Indeed, knockdown of either PTEN
or ZEB2 increased proliferation of TB13602 cells (Figure 6A)
and WM35 cells (Figure 6B), whereas neither PTEN nor ZEB2
silencing significantly altered the proliferation rate of A375 cells
(Figure 6C). Importantly, anchorage-independent growth in soft
agar was enhanced by depletion of PTEN or ZEB2 in all three
melanoma cell lines (Figures 6D–6F). We next determined
whether this ceRNA crosstalk would be operational in vivo. To
this end, we lentivirally delivered a short hairpin against ZEB2
to TB13602 cells and examined their oncogenic properties.
shRNA-mediated knockdown of ZEB2 lowered expression of
PTEN (Figure 6G), accelerated proliferation (Figure 6H), and
increased the in vivo growth of xenografted tumors in nude
mice (Figure 6I). These data support the notion that ZEB2 has
tumor-suppressive activity in melanoma cells, which is, at least
in part, due to ZEB2 mRNA-mediated regulation of PTEN
expression.
Functional Crosstalk of ZEB2 and PTEN in Human
Cancer
We reasoned that, if PTEN and ZEB2 expression is linked
through several shared miRNAs, then their mRNA expression
levels might be coregulated. We interrogated mRNA levels in
a set of human primary melanoma samples (Halaban et al.,
2009) and found that PTEN and ZEB2 expression indeed signif-
icantly correlated (Figure 7A). Using the same set of expression
data, we asked whether PTEN and ZEB2 expression is dimin-
ished in melanomas compared to normal melanocytes. Neither
PTEN nor ZEB2 mRNA was significantly decreased in mela-
nomas in this data set (Figure S5A), which is in line with the
finding that PTEN expression is lost in only 30% of melanomas
(Tsao et al., 2004). We therefore examined whether decreased
ZEB2 expression would be evident in tumors with reduced
PTEN levels. We subdivided the tumor specimens into two(C) ZEB2 expression is efficiently reduced following treatment of HCT116 cells
expression of PTEN and ZEB2.
(D) Activation of AKT following ZEB2 depletion is miRNA dependent. Western b
(Bottom) Quantification of three independent western blot analyses.
(E and F) Overexpression of ZEB 30UTR increases PTEN 30UTR reporter activity. A
PTEN30UTR reporter and expression plasmids containing either the PTEN 30UTR
graph depicts the fold increase in RLU when PTEN 30UTR or ZEB2 30UTR was e
(G) Overexpression of ZEB2 30UTR or PTEN 30UTR increases PTEN levels in A37
(Bottom) Quantification of PTEN expression in three independent experiments.
(H) Western analyses showing PTEN expression in response to ZEB2 30UTR over
three independent western blot analyses.
(I) Effect of overexpression of the ZEB2 30UTR on the activity of a luciferase-PTE
Data are represented as mean ± SEM. NC, negative control (nontargeting siRNAgroups: melanomas with PTEN expression above average
(‘‘PTEN high’’) and tumors with PTEN expression below average
(‘‘PTEN low’’). Intriguingly, when compared to normal melano-
cytes, ZEB2 expression was significantly decreased only in the
‘‘PTEN low’’ subset (Figures 7B and Figure S5A), suggesting
that ZEB2 and PTEN mRNAs may coregulate each other in
melanoma.
We further determined whether the PTEN-ZEB2 relationship is
specific to melanoma or whether other tumor types display
a similar mode of PTEN regulation. Indeed, we identified signifi-
cant coexpression of PTEN and ZEB2 in primary prostate cancer
(Figure 7C). Moreover, ZEB2 expression is significantly reduced
in primary prostate cancer samples with a ‘‘PTEN low’’ expres-
sion profile (i.e., PTEN expression level below average) when
compared to normal prostatic epithelium or all prostate tumors
(Figures 7D and S5B). We analyzed three additional mRNA
expression data sets for melanoma, colon carcinoma, and glio-
blastoma and found that both PTEN and ZEB2were significantly
downregulated in these tumors when compared to normal tissue
(Figures 7E–7G). Finally, by interrogating human-mouse
conserved and human-specific mRNA coexpression networks,
we found that PTEN and ZEB2 mRNA show a significant corre-
lation of coexpression in several human tissues (Figure S5C).
Taken together, our data demonstrate that ZEB2 sequesters
miRNAs from PTEN and thereby regulates PTEN expression.
This mode of PTEN regulation was identified in murine and
human melanomas, as well as human prostate, colon, and brain
cancer.
DISCUSSION
We report here the identification, functional characterization, and
relevance of ceRNAs in cancer biology in vivo. By means of
a forward genetics approach using Sleeping Beauty insertional
mutagenesis in a mouse model of melanoma, we discovered
multiple putative ceRNAs for the tumor suppressor PTEN.
Further in vitro characterization validated the EMT regulator
ZEB2 as a PTEN ceRNA, and human cancer data corroborated
its functional relationship with PTEN. We therefore provide
evidence that aberrant regulation of PTEN via miRNA competi-
tion by ceRNAs contributes to melanoma development.
The results presented here further support our hypothesis that
protein-coding mRNAs communicate and coregulate each other
through competition for miRNAs that target both transcripts (Sal-
mena et al., 2011; Tay et al., 2011). Importantly, as regulationwith ZEB2 siRNA. qRT-PCR analysis of HCT116 cells treated with siRNA for
lot for pAKT and total AKT in WT and Dicer null HCT116 cells is shown (top).
375 (E) or TB13602 (F) melanoma cells were cotransfected with the luciferase-
or ZEB2 30UTR, followed by luciferase activity measurement 3 days later. The
xpressed compared to an empty control vector.
5 cells. Western blot for PTEN and HSP90 as a loading control is shown (top).
expression in WT and Dicer null HCT116 cells (top). (Bottom) Quantification of
N 30UTR reporter in WT and Dicer null HCT116 cells is shown.
pool). See also Figure S4.
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Figure 5. Characterization of miRNAs that Are Common to PTEN and ZEB2
(A) miRNA response elements (MREs) shared by PTEN and ZEB2. This table depicts the ninemiRNAs that the 30UTRs ofPTEN and ZEB2 have in common, as well
as the number of sites for each miRNA.
(B) Multiple miRNAs target both PTEN and ZEB2. Western analysis of PTEN and ZEB expression in TB13602 melanoma cells treated with the indicated miRNAs
is shown. Actin expression is shown as a loading control. Quantification of the western blot is shown in the bottom panel.
(C) Expression of common miRNAs in A375, WM35, and TB13602 melanoma cells as determined by qRT-PCR. n.d., not detectable.
(D) MS2-RIP followed by qRT-PCR to identify endogenous miRNAs associated with the PTEN and ZEB2 30UTRs.
(E) MS2-RIP followed by qRT-PCR to identify miRNA binding to the PTEN 30UTR in cells depleted for PTEN or ZEB2.
NC, negative control (nontargeting siRNA pool). Data are represented as mean ± SEM.through miRNA sequestration is solely based on MREs, our find-
ings ascribe a predictable and protein coding-independent func-
tion to mRNA molecules. Furthermore, we establish a means of390 Cell 147, 382–395, October 14, 2011 ª2011 Elsevier Inc.regulatory interaction betweenmRNAs that is based onMREs as
functional units. MREs can be found on both protein-coding and
noncoding mRNAs, thus challenging the notion that mRNAs are
mere blueprints for peptide synthesis. Though other examples of
coding-independent functions of mRNAs have been previously
described (Candeias et al., 2008; Jenny et al., 2006), our findings
bestow on any RNA molecule functions that may be predicted
based on their MRE sequence (Salmena et al., 2011). Our find-
ings of a microRNA-mediated andMRE-dependent gene regula-
tory ceRNA dimension are corroborated by two other studies
demonstrating ceRNA activity for protein coding (Sumazin
et al., 2011 [this issue of Cell]) and noncoding RNA (Cesana
et al., 2011 [this issue of Cell]) molecules.
Using bioinformatics approaches and in vitro experimental vali-
dation, we have successfully predicted and characterized several
ceRNAs that regulate the tumorsuppressorPTEN(Tayetal., 2011).
In the work presented here, we undertook an unbiased genetic
in vivo approach to uncover mutational events that cooperate
with oncogenic BRAF to promote melanoma development. Not
only did this approach identify PTEN, a known cooperator of
oncogenic BRAF in melanoma, but it also generated a list of CIS
that was significantly enriched for putative PTEN ceRNAs. Thus,
our genetic approach represents an alternative and more func-
tional way of identifying PTEN ceRNAs, which complements our
bioinformatics-based ceRNA prediction method.
We have previously used the rna22 prediction algorithm in
conjunction with ten validated, 30UTR-binding PTEN miRNAs
(miR-17-5p, miR-19a, miR-19b, miR-20a, miR-20b, miR-26a,
miR-26b, miR-93, miR-106a, and miR-106b) to predict PTEN
ceRNAs (Tay et al., 2011). To screen the murine melanoma CIS
for candidate PTEN ceRNAs, we instead employed TargetScan,
as this algorithm considers MRE conservation between
mammals. TargetScanpredictedPTENas a target for 39different
miRNAs (Table S1), which were used to screen the Sleeping
Beauty CIS to identify putative PTEN ceRNAs. However, we
also compared our list of 320 CIS with the rna22-generated list
of putative PTEN ceRNAs and found an overlap of four genes:
CNOT6L, MEF2A, PDS5B, and ROCK2. These four putative
PTEN ceRNAs were not predicted by TargetScan, which is due
to the fact that TargetScan considers the miR-17-5p/20ab/93/
106ab/519, miR-19ab, and miR-26ab families each as single
MREs, whereas we considered them as individual MREs for our
rna22-based prediction of PTEN ceRNAs. Thus, though
CNOT6L, MEF2A, PDS5B, and ROCK2 share more than seven
MREs with PTEN if they are considered individually (rna22
approach), they fall under the threshold of seven MREs if each
miRNA family is considered as oneMRE (TargetScan approach).
Therefore, rna22 and TargetScan prediction algorithms, as well
as the use of only validated or all predicted MREs, can success-
fully be used to predict PTENceRNAs. These findings are of great
relevance, as they validate and generalize our MuTaME predic-
tions irrespective of the algorithms employed.
We have proposed a set of rules and a methodology to vali-
date and characterize ceRNAs (Tay et al., 2011). By applying
thismethodology, we have confirmed thatZEB2 acts as a ceRNA
for the tumor suppressor PTEN. Indeed, we found a significant
correlation between the expression of ZEB2 and PTEN in human
melanomas and prostate cancer (Figure 7). Moreover, compared
to benign tissues, ZEB2 expression was significantly reduced in
tumors with low PTEN expression levels (Figure 7). Thus, ZEB2
has tumor-suppressive properties. The ZEB2 protein promotesEMT by repressing expression of E-Cadherin (Vandewalle
et al., 2005) and thus may be involved in promoting cancer
progression and metastasis in some instances of epithelial
cancers. Indeed, the miR-200 family regulates expression of
ZEB2 (Gregory et al., 2008; Korpal et al., 2008; Park et al.,
2008) and is commonly associated with EMT and cancer
progression (Mezzanzanica et al., 2010; O’Day and Lal, 2010;
Pang et al., 2010). In melanoma cells, miR-200 does not appear
to repress EMT and invasion, but rather, different miR-200 family
members mediate alternative modes of melanoma cell migration
(Elson-Schwab et al., 2010). It has been reported that ZEB2
expression is suppressed by p53-mediated upregulation of
miR-200 (Kim et al., 2011), suggesting that p53 deficiency
promotes EMT through induction of ZEB2. However, p53 muta-
tions are rare in melanoma (http://www.sanger.ac.uk/genetics/
CGP/cosmic/), making upregulation of ZEB2 via this route
unlikely. Moreover, whether EMT is involved in progression of
cancers of nonepithelial origin, such as melanoma, is unclear.
We hypothesized that, in certain instances, mRNA and protein
encoded by the same gene may exert different biological effects
(Salmena et al., 2011). ZEB2 powerfully exemplifies such a case,
acting as a tumor suppressor by regulating PTEN expression
through its mRNA in melanoma, whereas the protein promotes
tumor progression and metastasis by controlling EMT in epithe-
lial cancers.
Insertional mutagenesis screens using retroviruses or transpo-
sons have been widely used to discover cancer genes. Our work
encourages the integration of the classic ‘‘protein dimension’’
with an additional ‘‘ceRNA dimension’’ when analyzing the
‘‘hits’’ of such screens. By doing so, genes that are initially clas-
sified as false positives based on their protein function may, in
fact, be cancer-promoting genes by means of their ceRNA
activity. In addition, previously performed insertional mutagen-
esis screens couldbe re-interrogated for thepresenceof ceRNAs
of prominent cancer genes using bioinformatics MRE prediction
methods described here and in Tay et al. (2011). This may reveal
a so far unappreciated genetic dimension, with a role in cancer
development and the pathogenesis of other human conditions.
EXPERIMENTAL PROCEDURES
Plasmids
The 30UTRs of mouse and human ZEB2 and human PTEN were amplified by
PCR from genomic DNA and cloned into pCDNA3 or pCMV according to stan-
dard procedures. Generation of PTEN30UTR-psiCHECK-2 is described by Tay
et al. (2011). Primer sequences are available upon request.
Cell Culture and Transfection
A375, WM35, 451Lu, and WM278 human melanoma cells were obtained from
M. Herlyn (Wistar Institute) and cultured as previously reported (Tsao et al.,
2004). TB13602, HCT116 wild-type, and Dicer/ cells were grown in Dulbec-
co’s modified Eagle’s medium (DMEM) supplemented with 10% FCS, peni-
cillin/streptomycin, and glutamine at 37C in a humidified atmosphere with
5% CO2. Cells were transfected with 100 nM siRNAs and Dharmafect 1 or
1.5 ug of plasmid DNA and Lipofectamine 2000 in 12-well plates according
to the manufacturer’s recommendations for transfection.
Western Blot Analysis
Cells were lysed in RIPA buffer containing Complete Mini protease inhibitors
(Roche) and a Phosphatase Inhibitor cocktail (Sigma). Total protein (5–20 mg)Cell 147, 382–395, October 14, 2011 ª2011 Elsevier Inc. 391
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Figure 6. ZEB2 Displays Tumor-Suppressive Properties in Melanoma Cells
(A–C) Proliferation curves of TB13602 (A), WM35 (B), and A375 (C) melanoma cells treated with siPTEN, siZEB2, and NC are shown.
(D–F) Anchorage-independent growth in soft agar. Representative pictures of TB13602 (D),WM35 (E), and A375 (F) are shown on the right, and quantifications are
shown on the left.
(G) Western blot showing ZEB2 and PTEN expression in TB13602 cells infected with shZEB2 and shGFP pLKO.1 lentiviruses (top). (Bottom) Quantification of
western analysis.
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Figure 7. Functional Crosstalk of PTEN and ZEB2 in Human Cancer
(A) mRNA expression of PTEN and ZEB2 correlates in human melanoma. Graph showing mRNA expression levels for PTEN and ZEB2 in human melanoma
samples, in which each dot corresponds to one tumor sample. Pearson score shows a positive and significant correlation.
(B)ZEB2mRNAexpression is significantly lower in humanmelanomaswith reducedPTEN expressionwhen compared to normal melanocytes. Box plot depicting
mRNA expression levels for PTEN and ZEB2 in normal melanocytes and ‘‘PTEN low’’ tumors (melanomas with PTEN mRNA expression below the average).
(C) Correlation of PTEN and ZEB2 mRNA expression in human prostate cancer samples. Similar to (A), each dot represents one tumor sample. Pearson score
shows a positive and significant correlation.
(D) ZEB2 expression is significantly reduced in prostate tumors with low PTEN mRNA expression levels. Box plot showing PTEN and ZEB2 mRNA expression
levels in normal adjacent prostate and primary prostate adenocarcinoma.
(E–G) Additional mRNA expression data sets showing reduced PTEN and ZEB2 mRNA levels in melanoma (E), colon carcinoma (F), and glioblastoma (G)
compared to normal tissue.
In the box plots, the top and bottomboxes represent the 75th and 25th percentile, respectively, and thewhiskers represent theminimum andmaximum of all data
points. See also Figure S5.was subjected to SDS-PAGE on 4%–12%Bis-Tris acrylamide NuPAGE gels in
MOPS SDS buffer (Invitrogen). The following primary antibodies were used:
HSP90 (BD), PTEN, phospho-AKT (p473), and total-AKT (Cell Signaling) and(H) Proliferation curves of cells shown in (G).
(I) Quantification of xenograft tumor volume of TB13602 cells infected with shZE
Data are represented as mean ± SEM. NC, negative control (nontargeting siRNAZEB2 and actin (Santa Cruz Biotechnologies). Subsequently, membranes
were incubated with secondary HRP-tagged antibodies (Amersham), and
signals were visualized with ECL or ECL plus (Amersham).B2 and shGFP pLKO.1 lentiviruses.
pool).
Cell 147, 382–395, October 14, 2011 ª2011 Elsevier Inc. 393
RNA Extraction and Real-Time PCR
For real-time PCR analyses, total RNA was extracted using the Qiashredders
and RNeasy Mini Kit (QIAGEN) according to the manufacturer’s recommenda-
tions. cDNA was synthesized using the High Capacity cDNA Reverse
Transcriptase Kit according to the manufacturer’s instructions (Applied
Biosystems) and was analyzed by real-time PCR using taqman gene expres-
sion assays (Applied Biosystems) on a LightCycler 480 System (Roche Applied
Science).
Luciferase Assays
TB13602 or A375 cells were transfected with 150 ng of empty psiCHECK2
vector or psiCHECK2-PTEN30UTR and either 100 nM siRNA or 1 mg 30UTR
vector constructs using Lipofectamine 2000 according to manufacturer’s
recommendations. In all transfections, firefly luciferase activity was used as
a normalization control for transfection efficiency. Seventy-two hours after
transfection, luciferase activities were measured consecutively with the dual
luciferase reporter system (Promega) using a luminometer (Promega).
Cell Proliferation
Cells were plated in triplicates in 12-well plates at a final density of 2 3 104/
well. On days 1–4 after plating, cells were washed with PBS, fixed in 4%
PFA, and stained with crystal violet. The dye was extracted with 10% acetic
acid, and absorbance at 595 nm was determined.
Xenografts
13 106 TB13602 cells were mixed with Matrigel and injected into the flanks of
NCR nude mice. Tumor growth was measured after 14 days and the volume
calculated using the formula 0.5 3 L 3 W 3 H.
Statistical Analysis
In vitro data were analyzed using unpaired Student’s t test. Values of p < 0.05
were considered statistically significant. *p < 0.05; **p < 0.01; ***p < 0.001. The
mean ± SE of three or more independent experiments performed in triplicates
is reported.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures, five
figures, and one table and can be found with this article online at doi:10.
1016/j.cell.2011.09.032.
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